| ChiCGB vs BEAM in High-risk or R/R Lymphomas (NCT05466318) | Sichuan University | 2022-07-01 |
| Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL (NCT05186558) | The First Affiliated Hospital with Nanjing Medical University | 2022-05-15 |
| Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA (NCT04763148) | Herlev Hospital | 2022-01-12 |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study (NCT04982471) | Celgene | 2021-11-03 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT (NCT04789434) | Ruijin Hospital | 2021-07-09 |
| A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) (NCT04790903) | Hoffmann-La Roche | 2021-07-02 |
| Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (NCT05784415) | AIDS Malignancy Consortium | 2021-05-22 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT05318391) | Shanghai Zhongshan Hospital | 2021-04-14 |
| PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT (NCT04799314) | Ruijin Hospital | 2021-04-01 |
| Fatigue Reduction Diet in Lymphoma Survivors (NCT05327725) | Ohio State University Comprehensive Cancer Center | 2021-03-15 |
| A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) (NCT04660799) | Hoffmann-La Roche | 2021-02-24 |
| LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (NCT04446962) | Institut Curie | 2020-10-30 |
| Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab (NCT04214444) | University Hospital, Tours | 2020-07-03 |
| 18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma (NCT04317313) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-04-01 |
| Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression (NCT03977623) | Samsung Medical Center | 2019-09-24 |
| GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL (NCT04021992) | Sun Yat-sen University | 2019-07-15 |
| Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL (NCT04022005) | Sun Yat-sen University | 2019-06-19 |
| CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410) | Chongqing Precision Biotech Co., Ltd | 2019-06-01 |
| Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (NCT04183569) | University Hospital, Bordeaux | 2019-02-19 |
| Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines (NCT05728632) | Giulio Stefanini | 2019-01-01 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients (NCT03600363) | Ruijin Hospital | 2018-09-01 |
| Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) (NCT03483103) | Juno Therapeutics, a Subsidiary of Celgene | 2018-07-27 |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma (NCT03357627) | Calithera Biosciences, Inc | 2018-02-16 |
| Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects (NCT03629873) | The First Affiliated Hospital with Nanjing Medical University | 2018-02-01 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019) | Fudan University | 2017-12-21 |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (NCT03310619) | Celgene | 2017-12-20 |
| Durvalumab in DLBCL After Autologous Transplant (NCT03241017) | Insel Gruppe AG, University Hospital Bern | 2017-10-01 |
| Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) (NCT03211702) | Chonbuk National University Hospital | 2017-08-25 |
| Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis (NCT03293173) | Nordic Lymphoma Group | 2017-08-04 |
| R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL (NCT03018626) | Nanfang Hospital, Southern Medical University | 2017-07-27 |
| Thalidomide Maintenance Treatment in DLBCL (NCT03016000) | Nanfang Hospital, Southern Medical University | 2017-07-26 |
| Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response (NCT03154710) | Weprom | 2017-07-12 |
| A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03135262) | Hoffmann-La Roche | 2017-06-15 |
| T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas (NCT03049449) | National Cancer Institute (NCI) | 2017-03-17 |
| A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma (NCT03003520) | Celgene | 2017-02-28 |
| Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL (NCT02987400) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2017-01-04 |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02653989) | Medivation, Inc. | 2016-12-01 |
| Cell-free Circulating DNA in Primary Cutaneous Lymphomas (NCT02883517) | University Hospital, Bordeaux | 2016-11-22 |
| Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (NCT02763254) | Cell Medica Ltd | 2016-11-01 |
| 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma (NCT02928861) | Peking University Cancer Hospital & Institute | 2016-10-01 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma (NCT02743546) | Janssen Research & Development, LLC | 2016-07-20 |
| a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies (NCT02846584) | Southwest Hospital, China | 2016-07-01 |
| A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma (NCT02776891) | University of California, San Francisco | 2016-06-13 |
| the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) (NCT02737085) | Southwest Hospital, China | 2016-03-01 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (NCT02669017) | ADC Therapeutics S.A. | 2016-03-01 |
| To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL (NCT02624492) | Boehringer Ingelheim | 2016-01-28 |
| RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor (NCT03536039) | Andres J. M. Ferreri | 2016-01-27 |
| Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma (NCT02592876) | Seagen Inc. | 2015-10-01 |
| An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma (NCT02413489) | Janssen Research & Development, LLC | 2015-09-02 |
| R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma (NCT02428751) | Wenqi Jiang | 2015-09-01 |
| Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma (NCT02555267) | Chonbuk National University Hospital | 2015-09-01 |
| A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (NCT02417285) | Celgene | 2015-05-22 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma (NCT02343536) | Celgene | 2015-04-29 |
| A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) (NCT02278796) | Insel Gruppe AG, University Hospital Bern | 2015-04-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (NCT02285062) | Celgene | 2015-02-17 |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas (NCT02181218) | Washington University School of Medicine | 2015-02-04 |
| Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT02086604) | Washington University School of Medicine | 2014-09-18 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma (NCT02031419) | Celgene | 2013-12-18 |
| Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM (NCT02364050) | Fondazione Italiana Linfomi - ETS | 2013-09-01 |
| Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (NCT01925612) | Seagen Inc. | 2013-08-01 |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma (NCT01786135) | Seagen Inc. | 2013-02-01 |
| A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma (NCT01649856) | Hoffmann-La Roche | 2012-08-24 |
| Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients (NCT01357733) | The Catholic University of Korea | 2012-03-02 |
| Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (NCT01421524) | Celgene | 2011-09-12 |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01421667) | Seagen Inc. | 2011-08-01 |
| A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab (NCT01307267) | Pfizer | 2011-06-21 |
| A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib (NCT01324596) | University Hospital Southampton NHS Foundation Trust | 2011-04-01 |
| Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma (NCT01181999) | Chonnam National University Hospital | 2010-08-01 |
| 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy (NCT01156259) | Chinese Academy of Medical Sciences | 2010-04-01 |
| The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) (NCT01266668) | Chonbuk National University Hospital | 2010-02-01 |
| Lenalidomide and R-CHOP in B-cell Lymphoma (NCT00901615) | Lymphoma Study Association | 2009-01-06 |
| Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) (NCT00864227) | Medical College of Wisconsin | 2008-12-01 |
| Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) (NCT00849147) | Medical College of Wisconsin | 2008-10-01 |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL (NCT00655837) | Seagen Inc. | 2008-04-01 |
| Coproporphyrine Isomers and Methotrexate Elimination (NCT00822432) | Assistance Publique - Hôpitaux de Paris | 2007-10-01 |
| A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL (NCT00529503) | Seagen Inc. | 2007-09-01 |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NCT00435916) | Seagen Inc. | 2006-12-01 |
| R-CHOP + GM-CSF for Previously Untreated LCL in Elderly (NCT00582725) | University of Wisconsin, Madison | 2002-03-01 |
| EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection (NCT00006436) | National Cancer Institute (NCI) | 2001-01-29 |
| Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol (NCT04400591) | Juno Therapeutics, a Subsidiary of Celgene | |